Global Health Partner presentation Q3 2012

323 views

Published on

Global Health Partner Q3 2012 presentation

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
323
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Global Health Partner presentation Q3 2012

  1. 1. GLOBAL HEALTH PARTNER Q3 REPORT 2 NOVEMBER, 2012 Marianne Dicander Alexandersson, CEO Tobias Linebäck, CFO
  2. 2. AgendaQ3 performanceMarket trends and opportunitiesFocus going forwardActions taken so farFigures and graphsFinancial summary 2
  3. 3. Disappointing performance in Q3 • Disappointing growth and profitability • 7 percent growth • EBIT -13 MSEK (-12) (accumulated EBITDA 12,3 MSEK) • Effects from lost contracts with county councils • Continued tough market situation in Sweden and Denmark with intense competition and depressed prices 3
  4. 4. Market trends and opportunities in Sweden • Strong political focus on profitsPOLITICS/MEDIA • Quality, openness and long-term perspective • Increasing patient powerPATIENT TRENDS • Patient free choice and insurance companies • High focus on pricePUBLIC TENDERS/ • NKI, New Karolinska, opportunities forFREE CHOICE SYSTEM elective care 4
  5. 5. Continued price pressure and consolidation in Denmark • Prolonged care guarantee will increasePOLITICS/MEDIA waiting times • Consolidation and squeeze out of smallerMARKET TRENDS providers • Price pressure from insurance companies • Accreditation requirement increases barriersQUALITY TRENDS of entrance 5
  6. 6. Revenues from insurance companies growing Private Insurance companiesin importance County councils Revenue distribution 100% 90% 20 17 18 16 21 80% 16 17 20 21 70% 31 60% 50% 40% 30% 63 63 63 61 53 20% 10% 0% 2009 2010 2011 2011 Jan-Sept 2012 Jan-Sept 6
  7. 7. Greater focus will increase profitabilityFROM… …TO Focus on • Growth in selected • Growth in Nordic region markets • Core business Process More Improve- patients ment 7
  8. 8. Actions taken so farFocus only on core business, where we can add value • Closure of Bariatric Center Copenhagen (Q2) • Sale of Bodylift center (Q3) • Sale of Nacka property (Q3)Focus on growth in the Nordic region • Acquisition of Odenplan (Q4) • Sale of Cairo (Q4) • Opening of Orthocenter Skåne in Malmö (Q4) 8
  9. 9. Continued challenging market Q3SEK millions Revenue • 7 percent growth - revenue increased from 129 to 138 • 6 percent accumulated growth – revenue increased from 488 to 518 • 11 percent growth in Q3 from Danish acquisition • Also growth from areas where there is high patient power 129 138 • Negative organic growth due to • Lost VGR contracts • Continued high competition and price pressure • Increasingly strong positions with insurance companies, 2011 2012 provides a solid base for future positioning in the market place Revenue rolling 12 months 800 689 704 700 666 559 624 600 675 696 • Rolling 12 months continue to increase and now amounts 500 646 544 586 to SEK 704 million 400 300 • The acquisition of Gildhöj constituted the growth 200 100 for the third quarter 0 Kv2 Kv3 Kv4 Kv1 Kv2 Kv3 Kv4 Kv1 Kv 2 Kv 3 2010 2010 2010 2011 2011 2011 2011 2012 2012 2012 9
  10. 10. Weak performance – Q3 Q3SEK millions EBITA EBITA • Weak performance where especially SL Ortho/Spine is underperforming • One-off items of net +2,9 MSEK has affected the EBITA -12 -13 • Good performance in the Bariatric Service Line • Cost savings and volumes from VGR are paying off • Gastro is performing well overall • Adverse effects from continued hard price competition in tenders and effects from lost contract with VGR 2011 2012 • Average prices per procedure have in many cases decreased EBITDA with 20–30% during the last 5 years 57 56 60 49 50 • Actual price decrease 42 50 38 • Changed patient mix 40 • Efficiency has increased but not enough to 30 24 23 30 31 meet the significant price drops 20 • Continued measures are taken to adjust capacity 10 and costs and efficiency 0 • EBITDA for Q3 amounted to -4,9 which reduced the rolling 12 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 EBITDA to 23. 2010 2010 2010 2011 2011 2011 2011 2012 2012 2012 10
  11. 11. Service Line Ortho/Spine • Very strong provider of orthopaedic and spine treatments in Sweden • Organic growth only in clinic in Stockholm subject to free choice • Lost VGR contracts affect profitability • Challenge is to fully meet the heavy price reductions through increased efficiency • Price reductions in Denmark following tenders by insurance companies • Results below are affected by allocated segment costs amounting to -2.1 million in Q3 Full- Q3 Q3 Change 9 months 9 months Change year SEK millions 2012 2011 % 2012 2011 % 2011Revenue 81.0 73.1 11 319.0 265.9 20 379.6Operating profit* -9.4 0.3 6.1 28.5 35.3Operating margin, % -12 0 2.0 11.0 9* Excluding goodwill write-down of 7 MSEK in OPA in Q3 2012 11
  12. 12. Service Line Dental • Maintained revenue despite continued decline in market for dental implants. Market is believed to have stabilized • Reduced profitability due to less good patient mix • Also changed dynamics between referral dentists and specialists • Results below are effected by allocated segment costs amounting to 0 million in Q3 Q3 Q3 Change 9 months 9 months Change Full-yearSEK millions 2012 2011 % 2012 2011 % 2011Revenue 14.5 14.7 -1.0 66.6 64.5 3.0 92.3Operating profit* -1.1 -0.4 5.0 4.6 6.5Operating margin, % -8.0 -3.0 8.0 7.0 7.0* Excluding profit from sale of property in Q3 and write down of goodwill in full year 2011 and Q3 2012 12
  13. 13. Service Line Bariatrics• Heavy cost cuts and volumes from VGR are starting to pay off• Gastro clinic in Stockholm is growing and performing well• Market is still very tough and is characterized by high price pressure• During Q2 and Q3, efforts to focus business around core areas have begun • Bariatrics clinic in Copenhagen was closed during Q2 • Reconstructive plastic surgery clinic was sold during Q3 • Bariatrics clinic in Cairo was sold during Q4• Results below are affected by allocated segment costs amounting to -2.9 million in Q3 Q3 Q3 Change 9 months 9 months Change Full-year SEK millions 2012 2011 % 2012 2011 % 2011 Revenue 36.0 35.5 1 110.5 136.7 -19 174.7 Operating profit* -3.0 -5.2 -10.9 -2.0 -0.2 Operating margin, % -8 -15 -10 -1.0 0* Including one-off costs of 1,3 MSEK in Q3 and -4.6 in 9 months 13
  14. 14. Service Line Arrhythmia• Solid growth and profitability• Relatively stable future patient flow is expected• Results below are effected by allocated segment costs amounting to -0.4 million in Q3 Q3 Q3 Change 9 months 9 months Change Full-yearSEK millions 2012 2011 % 2012 2011 % 2011Revenue 6.3 5.8 9 21.4 21.3 0 28.6Operating profit 0.1 0.2 1.9 2.9 2.8Operating margin, % 2 3 9 14 10 14
  15. 15. Q3 2011Positive cash flow due to sale of property – Q3 Q3 2012SEK millions Comments • Weak operating cash flow in the third 20 quarter due to weak performance and some one-off costs 10 0 • Cash flow from investing activities -10 mainly consists of investments in health -20 care equipment and sale of property -30 in Nacka -40 • Cash flow from financing activities Operations Investments Financing Total cash flow include new loans as well as some loan repayments • Total cash flow is positive in Q3 due to sale of property. 15
  16. 16. Financial summary• Company working hard to change trend with falling EBITDA• Falling EBITDA has resulted in a break of one of the bank covenants. However, the bank has issued a waiver• Net debt under control, SEK 86 million in relation to e.g., turnover of SEK 704 million• Sale of property has released funds of 29 MSEK for use in GHPs core business• Weaker performance and increased focus on core business have caused one-off costs • Goodwill write-down of Nacka and OPA due to sale and lease back of real estate and volume drop, however not effecting cash • Other write-downs and reserves amounting to -4.5 MSEK 16
  17. 17. APPENDIX 17
  18. 18. Performance per geographic area – Q3SEK millions Q3 Q2 9 months 9 months 2012 2011 2012 2011 Revenue from business activities 103.4 101.8 408.6 420.4 SWEDEN Operating result from business activities -9.2 -5.5 -2.0 19.9 Revenue from business activities 30.5 19.5 95.8 43.2 NORDIC REGION Operating result from business activities -3.7 -6.6 -15.7 -8.1 Revenue from business activities 3.9 7.8 13.1 24.8 OTHER COUNTRIES Operating result from business activities -0.1 0.4 4.2 -0.1 Reported operating result* -13.0 -11.7 -13.5 11.7 Comments • All business development costs are included in the Swedish segment* All numbers excl. goodwill write downs 18
  19. 19. Reduced margins in mature business – Q3SEK millions Q3 Q3 9 months 9 months 2012 2011 2012 2011 Revenue 131.2 119.2 492.7 449.9 MATURE BUSINESS Operating result 1.1 2.3 28.6 46.8 NEWLY OPENED Revenue 6.6 9.9 24.8 38.5 AND DEVELOPMENT Operating result -14.1 -14.0 -42.1 -35.1 Reported revenue 137.8 129.1 517.5 488.4 Reported operating result* -13.0 -11.7 -13.5 11.7 Comments • Mature clinics are clinics that have been in operation for at least 24 months • Central administration costs for the Group are included in the mature business • Central expansion and project costs are included in the Newly opened and development business* All numbers excluding goodwill write downs 19
  20. 20. Financial key data – Q3 SEK millions Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 2012 2012 2012 2011 2011 2011 2011 2010 2010 2010 2010 2009 2009 2009Total cash 88 83 75 98 95 121 139 137 133 145 152 163 155 190Shareholders equity incl. 340 395 403 409 439 451 455 475 515 522 514 513 511 550minorityLong term debt 234 230 247 236 252 262 263 253 131 134 129 136 115 119Net cash position -86 -83 -102 -58 -66 -11 7 14 9 20 33 36 23 62Equity ratio 47 50% 50 % 54% 54% 55% 54% 54% 68% 67% 69% 68% 67% 69%Net debt / EBITDA rolling 12 3.4 3.43 2,7 1.4 1.3 0.19 n/a n/a n/a n/a n/a n/a n/a n/aInt bearing debt / EBITDA 7.6 7.2 4,9 3.8 3.2 2.4 2.4 2.5 4.0 6.1 11.7 16.8 11.6 28.9rolling 12Int bearing debt / adjusted 7.3 7.2 4,9 3.8 3.2 2.4 2.4 2.5 2.9 3.9 5.5 6.7 9.9 10.9EBITDA rolling 12EPS -0.81 -0.12 -0.05 -0.46 -0.19 0.09 0.04 0.13 -0.07 0.09 -0.01 -0.19 -0.19 -0.01Basic cash flow fromoperating activities per -0.41 0.35 -0.12 0.17 -0.27 0.19 0.00 0.38 -0.07 0.08 0.03 0.32 -0.32 0.05shareShareholders equity per 5.09 5.96 6,08 6.18 6.65 6.83 6.84 6.81 7.41 7.53 7.44 7.45 7.55 7.8share, SEKNumber of employees 382 382 355 372 364 360 367 324 306 302 297 288 281 282Revenue per employee 0.36 0.49 0.54 0.50 0.35 0.50 0.49 0.55 0.36 0.52 0.47 0.52 0.33 0.47 Note: The equity ratio has been re-calculated from the period Q4 2010 and onwards as a result of the change in accounting for put options. 20
  21. 21. www.globalhealthpartner.com Twitter: @ghpartnerContact:Marianne Dicander Alexandersson, CEO, +46 (0)705-62 85 55 marianne.dicander@ghpartner.comTobias Linebäck, CFO and IR, +46 (0)708-55 37 19, tobias.lineback@ghpartner.com 21

×